Cerulean Pharma Inc (NASDAQ:CERU) has been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $3.00.
Separately, Zacks Investment Research cut shares of Cerulean Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, January 11th.
Shares of Cerulean Pharma (NASDAQ:CERU) traded down 1.077% on Tuesday, reaching $0.643. 314,766 shares of the company’s stock were exchanged. Cerulean Pharma has a 12 month low of $0.63 and a 12 month high of $4.15. The firm’s 50-day moving average price is $1.19 and its 200 day moving average price is $0.97. The company’s market cap is $18.66 million.
About Cerulean Pharma
Cerulean Pharma Inc is a clinical-stage, oncology-focused company. The Company applies its Dynamic Tumor Targeting platform to develop differentiated therapies. Its platform utilizes nanoparticle-drug conjugates (NDCs), which consist of polymers that are covalently linked to anti-cancer therapeutics or payloads.
Receive News & Ratings for Cerulean Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.